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In recent years, recreational use of Salvia divinorum (Lamiaceae), a herbal drug that contains a
hallucinogenic ingredient, salvinorin A, has become a new phenomenon among young drug
users. In Taiwan, as in many other countries, dry leaves of S. divinorum and its related
concentrated extract products are available via the Internet. Besides S. divinorum, there are
many endemic Salvia species whose salvinorin A content is yet unknown. To understand the
abuse liability of these products, the aim of this study was to assess the concentration of
salvinorin A in endemic Salvia species and Internet-available salvinorin A-related products.
Samples of S. divinorumwerepurchasedvia the Internet and samples of eight endemic species
of Salviawere collected in Taiwan, including S. arisanensisHayata, S. coccinea Juss. ex Murr, S.
hayatana Makino ex Hayata, S. japonica Thumb. ex Murr, S. nipponica Miq. Var. formosana
(Hayata) Kudo, S. scapiformis Hance, S. tashiroi Hayata. Icon. PI. Formosan, and S. keitaoensis
Hayata. The content of salvinorin A was determined by high performance liquid chroma-
tography (HPLC). Salvinorin A was extracted from the dry leaves of S. divinorum and endemic
species of Salvia with methanol and analyzed on a C-18 column by isocratic elution with a
mobile phase of acetonitrileewater. Salvinorin A was detected in S. divinorum, but not in the
endemic Salvia species of Taiwan. Therefore, endemic species of Salvia in Taiwan may not
possess hallucinogenic potential. However, the potential harm from S. divinorum available via
the Internet should be thoroughly assessed in Taiwan, and control measures similar to those
implemented in many other countries should be considered.
Copyright ª 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.and PhD Program in Tox
n.
. Li).
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Salvia divinorum Epl. & Játiva-M. (Lamiaceae), which is endemic
to the northeastern Sierra Mazateca mountain region of
Mexico and traditionally used in spiritual rituals by the
Mazatec Indians to produce hallucinatory effects, is used for
traditional medicine purposes, including the treatment of
diarrhea, headache, anemia, and rheumatism [1]. S. divinorum
is ingested by chewing the fresh leaves, smoking the dry
leaves, or drinking the extraction solution of fresh leaves to
inducehallucinatory effects suchas “entering another reality”,
“dissociative sensations”, and “spatiotemporal dislocation”
[2,3]. Salvinorin A, a potent hallucinogenic ingredient isolated
from S. divinorum, is the primary non-nitrogenous neo-
clerodane diterpene selective agonist of naturally-occurring k-
opioid receptors [4]. The hallucinogenic mechanism of salvi-
norin A is different from those of classical hallucinogens, such
as lysergic acid diethylamide (LSD),69-tetrahydrocannabinol,
and ketamine, because it does not interact with 5-
hydroxytryptamine (5-HT) receptor (serotonin receptor),
cannabinoid (CB) receptor, or N-methyl¼D-aspartate (NMDA)
receptor [5,6]. Previous studies have estimated that smoking
approximately 200e500 mg of salvinorin A would be sufficient
to cause intense hallucinogenic and psychotomimetic effects
[7,8]. SalvinorinA is rapidly absorbedby inhalation,whether in
dry leaves or from a “concentrated extract” product; the
hallucinogenic effect can occur within about 30 seconds and
can last up to 20e30 minutes [7]. Oral administration causes
hallucination after about 5e10 minutes, and can last up to
1 hour [7]. Salvinorin A is rapidly degraded by blood esterase
and several cytochrome P450 isoenzymes, including CYP2E1,
CYP2C18, CYP1A1, and CYP2D6 [9,10]. The short psychoactive
effects of salvinorin A are due to rapid hydrolysis to the inac-
tive metabolite salvinorin B [9]. One study reported that the
elimination half-life of salvinorin A was short, at
56.6  24.8 minutes after intravenous administration [10]. In a
previous study, salvinorin Awasnot detected in urine samples
collected after 1.5 hours from two human volunteers who had
smoked S. divinorum dry leaves [11].
In recent years, S. divinorum has become increasingly
popular among adolescents and young adults. Babu et al [12]
indicated that S. divinorum has several features attractive to
young drug users and is a desirable hallucinogen substance:
(1) owing to the legality of S. divinorum, its related products are
easily purchased from various sources, including smart shops,
head shops, and online vendors; (2) sellers always declare thatFig. 1 e Dried leaves and related products of Salvia divinorum p
divinorum; (B) S. divinorum 100fx; (C) S. divinorum 30fx.evidence indicates that S. divinorum is safe and not addictive;
(3) salvinorin A may not be detected in urine because it has a
very short half-life [11].
According to the Substance Abuse and Mental Health Ser-
vices Administration (SAMHSA) publication, the 2006 National
Survey on Drug Use and Health (NSDUH) database, it is esti-
mated that 1.8 million adolescents or young adults have used
S. divinorum in their lifetime and 756,000 people have used S.
divinorum in the past year [13]. A previous study, analyzing the
2006e2008 NSDUH public-use data (N ¼ 166,453), indicated
that the lifetime prevalence of S. divinorum use has increased
by about 83% among individuals aged 12 years or older [14]. In
2010, the National Institute on Drug Abuse (NIDA) investigated
46,482 students in the 8th, 10th, and 12th grades from 396 public
and private schools and 5.5% reported having used S. divino-
rum, which is greater than other recreational drugs, including
heroin (0.9%), cocaine (2.9%), LSD (2.6%), methamphetamines
(1.5%), ecstasy (4.5%), g-hydroxybutyric acid (GHB) (1.4%), ke-
tamine (1.6%), and oxycodone (5.1%) [15,16].
S. divinorum has not been placed on the list of the United
Nations Drug Conventions, although it has become increas-
ingly popular in recent years. In 2002, Australia became the
first country to ban the possession and sale of S. divinorum [17].
In the USA, Missouri was the first state to restrict S. divinorum
use in 2003. Two years later, Louisiana became the first state to
pass a law regulating S. divinorum. In 2006, a Delaware teenager
named Brett Chidester used S. divinorum, which led to suicide,
and S. divinorum and salvinorin A were then placed on
Schedule I of Delaware’s Controlled Substances Act. In 2007,
the Drug Enforcement Administration (DEA) placed S. divino-
rum on the list of drugs of concern and into the preliminary
stages of drug regulation [18]. In 2008, the DEA reported that
nine states had passed a law controlling S. divinorum, four
states banned its use and sale, and seven states proposed
legislative bills, suggesting a tendency towards regulatory
control in the USA [19]. In Europe, Denmark, Germany, Latvia,
Italy, Sweden, Croatia, Romania, Lithuania, and Belgium have
placed bans on under-the-table sale of S. divinorum and salvi-
norin A; Poland has banned the possession and sale of S.
divinorumand its derivatives; Russia andSpainhaveprohibited
the possession and sale of S. divinorum plants. However, in
Norway, Iceland, Finland, and Estonia S. divinorum is legal for
medical purposes that include treatment of cocaine and her-
oin addiction. In Asia, Japan and South Korea have also placed
banson S. divinorumand salvinorinA trafficking [17]. In 2012, in
Hong Kong, S. divinorum was the subject of a proposed legis-
lative bill that suggested regulatory control [20].urchased from the Internet in Taiwan. (A) Dry leaves of S.
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divinorum (Fig. 1), as well as information on methods and
experience of use, have been available on the Internet in
Taiwan. Because S. divinorum has become a popular recrea-
tional drug and various Salvia species may contain opioid re-
ceptor agonists [21], it would be of interest to learn if
salvinorin A could be determined in various endemic Salvia
species in Taiwan. The aim of this study was therefore to
employ high performance liquid chromatography (HPLC) to
detect the presence of salvinorin A in substantial amounts in
S. divinorum and endemic species of Salvia in Taiwan.Fig. 3 e Effect of solvent and extraction days on the
extraction of salvinorin A (n [ 3). ACN (A) [ acetonitrile;
EtOH (:) [ ethanol; EA (╳) [ ethyl acetate; MeOH
(-) [ methanol.2. Materials and methods
2.1. Chemicals and samples
Salvinorin A (>97% purity) was purchased from ChromaDex
(Irvine, CA, USA). 4-Bromonitrobenzene (TCI, Tokyo, Japan)
was used as the internal standard (IS). Extraction solvents,
methanol, acetonitrile, ethyl acetate, and ethanol, used to
extract plant samples, were of analytical grade.
Dry leaves of S. divinorum and related concentrated extract
products, including S. divinorum 100fx (source specified asFig. 2 e Effect of themobile phase of acetonitrileewater on the re
A. (A) Acetonitrileewater (45:55, v/v) at a flow rate of 1.0mL/min; (
(C) acetonitrileewater (35:65, v/v) at a flow rate of 1.0 mL/min; (DCanada) and 30fx (source specified as Taiwan), were pur-
chased through the Internet in Taiwan. Endemic species of
Salvia, including S. arisanensis Hayata, S. coccinea Juss. Ex Murr,
S. hayatana Makino ex Hayata, S. japonica Thumb. ex Murr, S.
nipponica Miq. Var. formosana (Hayata) Kudo, S. scapiformistention of six Salvia species spikedwith 10 mg/mL salvinorin
B) acetonitrileewater (40:60, v/v) at a flow rate of 1.0mL/min;
) acetonitrileewater (35:65, v/v) at a flow rate of 1.5 mL/min.
Table 1 e Determination of accuracy and precision of
reference salvinorin A.
Concentration
known (mg/mL)
Concentration
found (mg/mL)
RSD (%) RE (%)
Intra-day (n ¼ 5)a
0.8 0.811  0.008 0.98 1.37
4.0 3.979  0.067 1.68 0.52
8.0 8.036  0.194 2.41 0.45
Inter-day (n ¼ 5)b
0.8 0.805  0.020 2.48 0.62
4.0 4.018  0.104 2.58 0.45
8.0 7.960  0.126 1.58 0.50
RE ¼ relative error; RSD ¼ relative standard deviation.
a Intra-day assay variance was validated with three known levels
of salvinorin A at five intervals in 1 day.
b Inter-day assay variance was validated with three levels of the
analyte on 5 successive days.
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Hayata, were collected from Xueshan, Aowanda, Yangming-
shan Park, Pingxisiaotzushan, Shihbaluohanshan, and Qing-
shui Mountain and confirmed by methods of pharmacognosy
in the laboratory of Dr Hsien-Chang Chang.2.2. HPLC conditions
The HPLC system consisted of a Hitachi L-2130 pump
(Schaumburg, IL, USA), a Waters 717 plus autosampler (Mil-
ford, MA, USA), and a Waters 486 UV detector (Milford, MA,
USA). The HPLC column was a Phenomenex Luna C-18
analytical column (250 4.6mm I.D., 5mm, Torrance, CA, USA),
which was coupled with a Phenomenex analytical guard
cartridge system (KJO-4282, Torrance, CA, USA) to protect the
analytical column in all analysis processes. HPLC de-
terminations were performed according to the method
described previously with slight modifications [22]. The mo-
bile phase of acetonitrile-water (35:65, v/v) was used for iso-
cratic elution at a flow rate of 1.5 mL/min, and column eluate
was detected by UV absorption at 208 nm.Table 2 e Precision of the slope and intercept of the regression
of salvinorin A in Salvia.
Sample (intra-day, n ¼ 5,
0.5e10 mg/mL)
Regression equation
S. divinorum y ¼ (0.0302  0.0009)x þ (0.0225  0.0004
S. divinorum 100fxa y ¼ (0.0306  0.0004)x þ (0.0132  0.0004
S. divinorum 30fxa y ¼ (0.0325  0.0006)x þ (0.0225  0.0008
S. arisanensisb y ¼ (0.0311  0.0013)x þ (0.0014  0.0004
S. coccineab y ¼ (0.0288  0.0007)x þ (0.0016  0.0007
S. hayatanab y ¼ (0.0286  0.0012)x þ (0.0009  0.0006
S. scapiformisb y ¼ (0.0298  0.0008)x þ (0.0005  0.0006
S. tashiroib y ¼ (0.0285  0.0011)x þ (0.0008  0.0006
S. nipponicab y ¼ (0.0289  0.0007)x þ (0.0005  0.0004
S. japonicab y ¼ (0.0300  0.0006)x þ (0.0005  0.0003
S. keitaoensisb y ¼ (0.0304  0.0009)x þ (0.0001  0.0005
RSD ¼ relative standard deviation; SD ¼ standard deviation.
a “Concentrated extract” products.
b Endemic species of Salvia in Taiwan.
c Mean  SD (n ¼ 5) with the % RSD values in parentheses.2.3. Preparation of standard solutions
Salvinorin A was weighed and dissolved in methanol to a
concentration of 1 mg/mL as the stock standard solution, and
thenworking standard solutions of 0.5, 0.8, 1.0, 2.5, 4.0, 5.0, 8.0,
and 10.0 mg/mL were prepared by dilution with methanol and
stored at 4C. The calibration curve of salvinorin A was made
using the working standard solutions, as analyzed by HPLC.
2.4. Extraction of samples
Leaf samples of endemic Salvia species were dried under the
shade before grinding to fine powder in a mortar. Dry leaves
and concentrated extract products of S. divinorum 30fx and
100fx were directly ground to fine powder. In this study, a
single extraction method as described by Gruber et al [22] was
performed with modifications. Briefly, the fine powder sam-
ples (100 mg) of ground leaf or concentrated extract products
were extracted in 100 mL extraction solution in a flask, fol-
lowed by shaking for 1 minute, sonication for 1 minute, and
steeping for 3 days. The purpose of sonication was to increase
contact surface areas of the fine powder samples with meth-
anol. Because longer sonication time (>2 minutes) resulted in
a substantial temperature increase, sonication for 1 minute
was adopted. The crude extracts were filtered with filter
paper, and the extraction was repeatedly washed with
appropriate amounts of methanol. The filtrates were evapo-
rated to dryness in a rotary evaporator. The dried solid sam-
ples were resolubilized with methanol to make a
concentration of 1 mg/mL.
2.5. Quantitative analysis of salvinorin A in S.
divinorum, concentrated extract products, and endemic
Salvia species of Taiwan
Before evaporation to dryness, the crude extracts of S. divino-
rum dry leaves and S. divinorum 100fxwere diluted 10-fold, and
that of S. divinorum 30fx was diluted 20-fold with methanol.
The dry solids were spiked with known levels of salvinorin A,equations by the standard addition method in the analysis
Correlation
coefficient (r)
Slopec Interceptc
) 0.9997 0.0302  0.0009 (2.9) 0.0225  0.0004 (1.6)
) 0.9999 0.0306  0.0004 (1.3) 0.0132  0.0004 (3.1)
) 0.9998 0.0325  0.0006 (1.8) 0.0225  0.0008 (3.9)
) 0.9997 0.0311  0.0010 (4.2) d
) 0.9998 0.0288  0.0007 (2.5) d
) 0.9999 0.0286  0.0012 (4.1) d
) 0.9998 0.0297  0.0008 (2.7) d
) 0.9999 0.0284  0.0011 (3.9) d
) 0.9999 0.0289  0.0007 (2.5) d
) 0.9999 0.0300  0.0006 (2.1) d
) 0.9999 0.0303  0.0009 (3.2) d
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j o u r n a l o f f o o d and d ru g an a l y s i s 2 2 ( 2 0 1 4 ) 3 7 0e3 7 8 375i.e., 0, 0.5, 1.0, 2.5, or 5.0 mg/mL with IS 4-bromonitrobenzene
(10.0 mg/mL) to make a redissolved solution of 1.0 mg/mL. Al-
iquots of 20 mL redissolved solutions were injected into the
HPLC system. Recovery of salvinorin A during the filtration
and evaporation processeswas investigated by adding 10.0 mg/
mL of salvinorin A to the endemic Salvia species of Taiwan.
The amount of salvinorin A present in the plant samples was
calculated from the peak area ratio of salvinorin A to the IS.3. Results
3.1. Separation conditions of the mobile phase
The mobile phase composition, modified by Gruber et al [22],
consisted of amixed extraction of six endemic Salvia species in
Taiwanspikedwith10mg/mLsalvinorinA. Fig. 2AandBshowed
that in the initialmobile phase of acetonitrileewater (45:55, v/v)
with a flow rate of 1.0 mL/min and the modification of the ace-
tonitrileewater (40:60, v/v) with a flow rate of 1.0 mL/min, the
salvinorin A peak was interfered with by the endogenous
components of the crude extraction of the mixed six endemic
Salvia species. In the modified mobile phase of acetonitrilee-
water (35:65, v/v) at a flow rate of 1.0 mL/min, the salvinorin A
peak was not eluted within 55 minutes (Fig. 2C). The modified
mobile phase of acetonitrileewater (35:65, v/v) with a flow rate
of 1.5 mL/min under isocratic elution had a better separation
efficiency in themixed extraction, leading to salvinorin A being
eluted at approximately 48.85minutes (Fig. 2D). Theoretically, a
shorter retention timecouldbeachievedwith shorteranalytical
columns, such as 150 4.6 5 mm. In this study, the separation
condition was not further approached because the analytical
evaluation of salvinorin A content in Salvia species for the
administrative purpose had been fulfilled.
3.2. Selection of extraction solvent and extraction time
Previous studies have used chloroform and acetonitrile to
extract salvinorin A from S. divinorum, but chloroform is more
toxic and extraction with acetonitrile probably requires a rela-
tively long time [8,22]. In this study,we triedmethanol, ethanol,
acetonitrile, and ethyl acetate as extraction solvents. The re-
sults shown inFig. 3 demonstrate the extraction conditions that
were selected: theuseofmethanolas theextractionsolvent and
steeping for 3 days; methanol extracted the contents of salvi-
norin A in S. divinorum at a greater efficiency than ethanol,
acetonitrile, orethyl acetate.Theextraction timewasoptimized
with steeping for 3 days, because this condition extracted the
maximum amount of salvinorin A from S. divinorum, and the
salvinorinAcontentdecreasedwith steeping for 4daysormore,Fig. 4 e Liquid chromatograms for (A) Salvia divinorum, (B) S. div
salvinorin A (10.0 mg), (C) S. arisanensis, (D) S. arisanensis spiked
S. coccinea spiked with IS (10.0 mg) and salvinorin A (10.0 mg), (G
salvinorin A (10.0 mg), (I) S. tashiroi, (J) S. tashiroi spiked with IS
japonica spiked with IS (10.0 mg) and salvinorin A (10.0 mg), (M)
salvinorin A (10.0 mg), (O) S. scapiformis, (P) S. scapiformis spiked
(R) S. keitaoensis spiked with IS (10.0 mg) and salvinorin A (10.0 m
A. High performance liquid chromatography (HPLC) conditions w
5 mm) and a mobile phase of acetonitrileewater (35:65, v/v) at aprobablydue to thedegradationorother biological causesof the
compounds in the crude extract of plant samples.
3.3. Method validation
Because salvinorin A is an endogenous component in the plant
samples, the accuracy of the method cannot be estimated
using a known concentration of salvinorin A in the crude
extraction of plant samples. The validation of the method for
determination of salvinorinA can be used as standard addition
for analysis of salvinorin A in Salvia species. To evaluate the
quantitative application of the method, five different concen-
trations over the range of 0.5e10.0mg/mL salvinorinA spiked in
Salvia species and a fixed concentration of IS were analyzed.
The linear regression equation was y ¼ (0.0288  0.0005)
x þ (0.0065  0.0002), with the correlation coefficient (r) above
0.999 (n ¼ 5). These data demonstrate the high linearity of this
method. The precision and accuracy of the proposed method
was evaluated on spiked salvinorin A in Salvia species and
estimated by relative standard deviation (RSD) and relative
error (RE). As shown in Table 1, the RSD and RE values of
different concentrations from high, medium, to low were all
below 2.6% and 1.4%, respectively. The limit of detection (LOD)
was determined by a signal-to-noise ratio of 3 (S/N¼ 3) and the
limit of quantification (LOQ) was determined by an S/N ratio of
10. The LOD and LOQ were 0.1 mg/mL and 0.5 mg/mL, respec-
tively. The LOD and LOQ were obtained from amixed solution
of six endemic Salvia species spiked with salvinorin A. The
precision of the slope and intercept of the regression equations
were estimated by standard addition analysis for salvinorin A
in the dry leaves of S. divinorum, the concentrated extract
products, and eight endemic Salvia species of Taiwan, and all
were less than 4.2% and 3.9%, respectively (Table 2). Salvinorin
A at 10.0 mg/mL was spiked in endemic Salvia species for the
recovery test. The peak area ratio of the tested chemical
standard was 10.0 mg/mL and the absolute recovery was
74.1  3.2% (n ¼ 3). From these results, better extractability of
Salvinorin A in endemic Salvia species was observed.
3.4. Qualitative and quantitative analyses of salvinorin
A in S. divinorum, concentrated extract products, and
endemic Salvia species of Taiwan
A qualitative study of salvinorin A from dry leaves of S.
divinorum, related products, and endemic Salvia species
involved spiking with 10 mg/mL salvinorin A to compare with
blank samples. The results are shown in Fig. 4. Salvinorin A
was not found in endemic Salvia species under the collection
conditions employed, but was only found in S. divinorum
purchased from the Internet in Taiwan. The salvinorin Ainorum spiked with internal standard (IS) (10.0 mg) and
with IS (10.0 mg) and salvinorin A (10.0 mg), (E) S. coccinea, (F)
) S. hayatana, (H) S. hayatana spiked with IS (10.0 mg) and
(10.0 mg) and salvinorin A (10.0 mg), (K) S. japonica, (L) S.
S. nipponica, (N) S. nipponica spiked with IS (10.0 mg) and
with IS (10.0 mg) and salvinorin A (10.0 mg), (Q) S. keitaoensis,
g). Peak 1 [ 4-bromonitrobenzene (IS); peak 2 [ salvinorin
ith a stationary phase of C-18 column (250 3 4.6 mm I.D.,
flow rate of 1.5 mL/min and UV detection at 208 nm.
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the various sources and collection conditions. The content of
the hallucinogen salvinorin A was analyzed by the standard
addition method for various plant samples spiked with sal-
vinorin A. The results of the quantitative analysis of salvinorin
A are shown in Table 3. The salvinorin A content in the dry
leaves of S. divinorum was 84.10  3.06 mg/100 mg. A previous
study indicated that dry leaf samples of S. divinorum contained
63e370 mg/100 mg [22]. As salvinorin A is an endogenous
substance, the various contents in S. divinorum were probably
subject to the influences of different sources, collection con-
ditions, or cultivation methods. The concentrated extract
products of S. divinorum 30fx (source specified as Taiwan) and
100fx (source specified as Canada) contained 163.97  6.48 mg/
100 mg and 55.75  1.73 mg/100 mg, respectively. The salvi-
norin A contents in the concentrated extract products were
claimed by the vendors to be standardized and concentrated.
According to previous studies, Tsujikawa et al [8] indicated
that a concentrated extract product labeled as being of a po-
tency of 2  e25  contained 410e3890 mg/100 mg, and
Wolowich et al [23] reported that a concentrated extract with a
labeled potency of 5  e20  contained 12.6e113.7 mg/100 mg.
The results indicated that the standardized contents of sal-
vinorin A in the concentrated extract products were lower
than that of S. divinorum dry leaves, which is similar to the
results reported by Tsujikawa et al [8].4. Discussion
The results of this study demonstrated that salvinorin A
could be detected in dry leaves of S. divinorum and its related
concentrated extract products, but not in the dry leaves of
endemic Salvia species of Taiwan, including S. arisanensis, S.
coccinea, S. hayatana, S. japonica, S. nipponica, S. scapiformis, S.
tashiroi, and S. keitaoensis. Siebert [7] reported that smoking
40e70 mg of the S. divinorum plant (equivalent to 200e500 mg
of salvinorin A) produced strong hallucinogenic effects that
lasted for about 20e30 minutes. The salvinorin A contents
in the dry leaves, 30fx (source specified as Taiwan), and
100fx (source specified as Canada) of S. divinorum were foundTable 3 e Contents of salvinorin A in plant samples.
Salvia species Source Colle
S. divinorum Internet in Taiwan
S. divinorum 100fxa Internet in Taiwan
S. divinorum 30fxa Internet in Taiwan
S. arisanensisb Xueshan
S. coccineab Aowanda
S. hayatanab Xueshan
S. scapiformisb Pingxisiaotzushan
S. tashiroib Shihbaluohanshan
S. nipponicab Yangmingshan Park
S. japonicab Yangmingshan Park
S. keitaoensisb Qingshui Mountain
a “Concentrated extract” products.
b Endemic species of Salvia in Taiwan.
c Mean  standard deviation (SD) (n ¼ 5).to be 84.10  3.06 mg/100 mg, 163.97  6.48 mg/100 mg, and
55.75  1.73 mg/100 mg, respectively. These results indicated
that the contents of salvinorin A in the related concentrated
extract products were significantly lower than that in dry
leaves of S. divinorum, and the concentration levels found
through content analysis were not of the labeled potency [8].
The results indicated that, under the collection time and
conditions, Salvia species endemic to Taiwanmay not become
recreational drugs in Taiwan. However, S. divinorum dry leaves
and related concentrated extract products have been available
via the Internet in Taiwan. Because they have various features
that are attractive to young drug users [12], S. divinorum will
probably become a new recreational drug. The abuse potential
of S. divinorum has been examined, and it has been reported
that the salvinorin A can produce a rewarding effect in the
conditioned place preference test, as well as inducing an in-
crease in dopamine levels in the nucleus accumbens shell,
which is considered to be associated with addiction behavior
[24e26]. Some reports have indicated that patients using S.
divinorum can experience psychotic symptoms and schizo-
phrenia, and one study reported that S. divinorum users had a
higher incidence rate of depression than that of nonusers [14].
An animal model demonstrated that attention and cognitive
deficits were induced by salvinorin A [14,16,27e29]. Violence
and suicidal behavior can take place after using S. divinorum
[30,31]. Concern has been increasing regarding the potential
harm caused by S. divinorum. Currently, S. divinorum and its
hallucinogenic ingredient salvinorin A are regulated in many
countries. The first country to control S. divinorum was
Australia, in which S. divinorum and salvinorin A were placed
on Schedule 9, which is defined as a prohibited sub-
stancedsubstances that may be abused or misused, the
manufacture, possession, sale, or use of which should be
prohibited by law except when required for medical or sci-
entific research, or for analytical, teaching, or training pur-
poses with the approval of Commonwealth and/or State or
Territory Health Authorities [32]. In the USA, many states,
including Florida, Virginia, Hawaii, Kentucky, Michigan, Min-
nesota, Connecticut, Missouri, Illinois, Oklahoma, Kansas,
Mississippi, Ohio, South Dakota, Georgia, Wyoming, Dela-
ware, Alabama, North Dakota, Indiana, Pennsylvania,ction/purchase date Concentration (mg/100 mg)c
2011.07.06 84.10  3.06
2011.07.06 55.75  1.73
2012.04.12 163.97  6.48
2011.06.16 d
2011.06.18 d
2011.07.06 d
2011.08.14 d
2011.07.22 d
2011.06.26 d
2011.06.26 d
2012.02.11 d
j o u r n a l o f f o o d and d ru g an a l y s i s 2 2 ( 2 0 1 4 ) 3 7 0e3 7 8 377Nebraska, and Colorado, have placed S. divinorum and/or sal-
vinorin A in Schedule I, which includes substances that have a
high potential for abuse and no currently accepted medical
use in the United States, and for which there is a lack of
accepted safety evidence for use of the drug or other sub-
stance under medical supervision [31,33]. Other states in the
USA, including Maryland, Tennessee, North Carolina, Louisi-
ana, California, West Virginia, Wisconsin, California, and
Maryland, have enacted specific age restrictions, particular
regulation or scheduling in order to control S. divinorum and/or
salvinorin A [31]. In Canada, S. divinorum and its main active
ingredient salvinorin A have been suggested to be listed on
Schedule III of the Controlled Drugs and Substances Act
(CDSA) [34]. Some countries in Europe, such as Belgium,
Croatia, Denmark, Germany, Italy, Latvia, Lithuania, Romania,
Sweden, Poland, Russia, and Spain, have strictly regulated or
banned S. divinorum and/or salvinorin A trafficking, posses-
sion, and/or sale. In Norway, Finland, Estonia and Iceland, S.
divinorum is legal only for medicinal purposes [17]. In Asia,
Japan and South Korea also banned S. divinorum and salvinorin
A trafficking, and Hong Kong has proposed regulatory controls
for S. divinorum and salvinorin A, because these substances
have a high potential for harm, and have unknown or are
unapproved for medical purposes [17,20]. However, S. divino-
rum and its related concentrated extract products have not
been regulated in Taiwan. The hallucinogenic substance sal-
vinorin A in S. divinorum has subsequently been reported to
have an addiction potential, risk of harm through intoxica-
tion, and tendency to increase drug abuse in several countries.
According to Nutt et al [35], the potential harm of new recre-
ational drugs and their related schedule level can be assessed
based on fact and scientific knowledge. Therefore, regulation
of S. divinorum/salvinorin A should be evaluated and the legal
status considered in Taiwan.5. Conclusions
In this study, we developed a method that improved the
extraction efficiency of salvinorin A in S. divinorum, and
established amethodmodified froma previous study to detect
salvinorin A in various Salvia species. The results indicated
that the hallucinogenic substance salvinorin Awas only found
in S. divinorum and its related concentrated extract products
but not in eight species of Salvia endemic to Taiwan under the
conditions of collection. S. divinorum-related products are
controlled in many countries because they could lead to
several health problems, such as addiction (dependence) po-
tential, abuse potential, and the potential to cause social
harm, and these products have become popular recreational
drugs among young drug users. Currently, definite medical
purposes of salvinorin A have not yet been proven. Therefore,
we suggest that S. divinorum and its related concentrated
extract products may need close scrutiny and should be
further assessed in Taiwan.Conflicts of interest
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